These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 16188664

  • 21. Iron chelation therapy in the management of transfusion-related cardiac iron overload.
    Fernandes JL.
    Transfusion; 2012 Oct; 52(10):2256-68. PubMed ID: 22404719
    [Abstract] [Full Text] [Related]

  • 22. Iron overload and toxicity: the hidden risk of multiple blood transfusions.
    Shander A, Cappellini MD, Goodnough LT.
    Vox Sang; 2009 Oct; 97(3):185-97. PubMed ID: 19663936
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Management of iron overload. Introduction.
    Cappellini MD.
    Blood Rev; 2008 Dec; 22 Suppl 2():S13. PubMed ID: 19059051
    [No Abstract] [Full Text] [Related]

  • 25. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
    Porter JB, Shah FT.
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
    [Abstract] [Full Text] [Related]

  • 26. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH, Wu KH, Tsai FJ, Peng CT, Tsai CH.
    Hemoglobin; 2006 Dec; 30(2):257-62. PubMed ID: 16798651
    [Abstract] [Full Text] [Related]

  • 27. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N.
    Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
    [Abstract] [Full Text] [Related]

  • 28. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ.
    Hemoglobin; 2008 Dec; 32(1-2):1-15. PubMed ID: 18274978
    [Abstract] [Full Text] [Related]

  • 29. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ, Kolnagou A.
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [Abstract] [Full Text] [Related]

  • 30. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C.
    Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract] [Full Text] [Related]

  • 31. [Pathogenesis of transfusional iron overload and iron chelation therapy].
    Ozawa K.
    Rinsho Ketsueki; 2009 Jul; 50(7):527-31. PubMed ID: 19638719
    [No Abstract] [Full Text] [Related]

  • 32. Iron: effect of overload and deficiency.
    Hider RC, Kong X.
    Met Ions Life Sci; 2013 Jul; 13():229-94. PubMed ID: 24470094
    [Abstract] [Full Text] [Related]

  • 33. Controversies surrounding iron chelation therapy for MDS.
    Leitch HA.
    Blood Rev; 2011 Jan; 25(1):17-31. PubMed ID: 21030120
    [Abstract] [Full Text] [Related]

  • 34. Optic neuropathy in iron overload and iron chelation therapy.
    Melachuri S, Lim CC, Winters J.
    Am J Hematol; 2022 May; 97(5):670-672. PubMed ID: 35179250
    [No Abstract] [Full Text] [Related]

  • 35. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M, Carrara P, Pinto V, Forni GL.
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract] [Full Text] [Related]

  • 36. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy.
    Shander A, Sazama K.
    Transfusion; 2010 May; 50(5):1144-55. PubMed ID: 20088842
    [Abstract] [Full Text] [Related]

  • 37. Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan.
    Kuo HT, Tsai MY, Peng CT, Wu KH.
    Hemoglobin; 2006 May; 30(2):291-9. PubMed ID: 16798654
    [Abstract] [Full Text] [Related]

  • 38. An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial.
    Rofail D, Viala M, Gater A, Abetz-Webb L, Baladi JF, Cappellini MD.
    Adv Ther; 2010 Aug; 27(8):533-46. PubMed ID: 20652657
    [Abstract] [Full Text] [Related]

  • 39. Iron chelation therapy for patients with sickle cell disease and iron overload.
    Inati A, Khoriaty E, Musallam KM, Taher AT.
    Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
    [No Abstract] [Full Text] [Related]

  • 40. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, Sobh H, Hamdy M, Sharaf I, Mostafa A, Shaker O, Hoffbrand AV, Taher A.
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.